Synthesis, anti-breast cancer activity, and molecular modeling of some benzothiazole and benzoxazole derivatives

Abstract

A new series of benzothiazoles and benzoxazoles was synthesized using 4-benzothiazol-2-yl-phenylamine and 4-benzoxazol-2-yl-phenylamine as starting materials. All the prepared compounds were evaluated for their antitumor activities against human breast cancer cell lines, MCF-7 and MDA-231, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability analysis. Almost all the tested compounds revealed potent antitumor activity, especially the N-methyl piperazinyl substituted derivatives 6f and 6c, which displayed the most potent inhibitory activity with IC50 values ranging from 8 to 17 nM. Docking the synthesized compounds into the epidermal growth factor receptor (EGFR), which is highly expressed in breast cancer, was employed to explore the possible interactions of these compounds with the EGFR. The activity of the reported compounds supports its clinical promise as a component of therapeutic strategies for cancer, for which high concentrations of chemotherapeutic agents are always a major limitation. A series of benzothiazoles and benzoxazoles was synthesized and screened against two breast cancer cell lines, MCF-7 and MDA-231. Almost all compounds revealed potent antitumor activity, especially 6f and 6c against both cell lines. © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.